Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

K. Begna · SciRah

Researcher profile · Semantic Scholar

K. Begna

Share profile

K. Begna — researcher profile on SciRah

h-index: 39
Works: 345
Citations: 6,728

Most-cited papers

Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Neil P. Shah, Ravi Bhatia, Jessica K. Altman, M. Amaya +29 more
2024The Journal of the National Comprehensive Cancer Network133 citations Open access
Semantic Scholar
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients
N. Gangat, Omer S Karrar, Moazah Iftikhar, Kristen B. McCullough +22 more
2023American journal of hematology/oncology73 citations Open access
Semantic Scholar
One thousand patients with essential thrombocythemia: the Mayo Clinic experience
N. Gangat, Omer S Karrar, A. Al-Kali, K. Begna +6 more
2024Blood Cancer Journal50 citations Open access
Semantic Scholar
Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent
N. Gangat, Azeem Elbeih, Nour Ghosoun, Kristen B. McCullough +33 more
2024American journal of hematology/oncology42 citations Open access
Semantic Scholar
Sodium‐glucose co‐transporter‐2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases
N. Gangat, Mostafa Abdallah, N. Szuber, Antoine N. Saliba +5 more
2023American journal of hematology/oncology26 citations Open access
Semantic Scholar
TP53 Mutations in Myeloproliferative Neoplasms: Context‐Dependent Evaluation of Prognostic Relevance
A. Tefferi, Maymona G. Abdelmagid, G. G. Loscocco, Saubia Fathima +17 more
2025American journal of hematology/oncology23 citations Open access
Semantic Scholar
Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations
M. Shah, Kevin Hung, A. Baranwal, M. Kutyna +33 more
2025Blood Advances22 citations Open access
Semantic Scholar
Pivekimab Sunirine (PVEK, IMGN632), a CD123-Targeting Antibody-Drug Conjugate, in Combination with Azacitidine and Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia
N. Daver, P. Montesinos, Jessica K. Altman, E. Wang +21 more
2023Blood17 citations Open access
Semantic Scholar
Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort
M. Shah, Kevin Hung, A. Baranwal, Gauri Wechalekar +33 more
2025Blood Cancer Journal16 citations Open access
Semantic Scholar
Multihit TP53 Mutations in Myeloproliferative Neoplasms and Acute Myeloid Leukemia: Comparative Analysis of Survival and Risk Factors in 142 Informative Cases
Saubia Fathima, Maymona G. Abdelmagid, Ali Alsugair, K. Begna +19 more
2025American journal of hematology/oncology13 citations Open access
Semantic Scholar
A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies
M. Davids, D. Brander, Y. Alvarado-Valero, C. Diefenbach +15 more
2024Blood Advances12 citations Open access
Semantic Scholar
Academic Community Partnership in Acute Promyelocytic Leukemia and Early Mortality
Anand P. Jillella, Sandra J. Lee, Jessica K. Altman, S. Luger +16 more
2025JAMA Oncology11 citations Open access
Semantic Scholar
Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent
Nickolas Steinauer, Kristen B. McCullough, A. Al-Kali, H. Alkhateeb +15 more
2024Haematologica11 citations Open access
Semantic Scholar
Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents
I. Johnson, Omer S Karrar, Masooma S. Rana, Moazah Iftikhar +14 more
2024British Journal of Haematology11 citations
Semantic Scholar
Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms
A. Baranwal, Mark Gurney, Rami Basmaci, Bahga Katamesh +18 more
2024Haematologica11 citations Open access
Semantic Scholar
CML and the WHO: Why?
Ellin Berman, Neil P. Shah, Michael Deninger, Jessica K. Altman +31 more
2023Journal of Clinical Oncology10 citations
Semantic Scholar
Characterisation and prognostic impact Of ZRSR2 mutations in myeloid neoplasms
Mahmoud Yacout, Bahga Katamesh, Yazan Jabban, Rong He +14 more
2024Leukemia9 citations Open access
Semantic Scholar
Efficacy and safety of pivekimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed Acute Myeloid Leukemia
N. Daver, A. Advani, A. de la Fuente-Burguera, P. Montesinos +21 more
2025Blood8 citations
Semantic Scholar
Triple A Plus (AAA +) Survival Prediction Model for Essential Thrombocythemia: Analysis Involving 7308 Patients
A. Tefferi, G. G. Loscocco, L. Rokach, T. Tadmor +18 more
2025American journal of hematology/oncology8 citations Open access
Semantic Scholar
Aspirin therapy is associated with a lower risk of pregnancy loss in both JAK2‐ and CALR‐mutated essential thrombocythemia—A Mayo Clinic study of 200 pregnancies
N. Gangat, Amritpal Singh, Rimal Ilyas, G. G. Loscocco +4 more
2024American journal of hematology/oncology8 citations Open access
Semantic Scholar
TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance
A. Tefferi, Maymona G. Abdelmagid, G. G. Loscocco, K. Begna +16 more
2024Blood7 citations Open access
Semantic Scholar
Reappraisal of mast cell leukemia based on a single institution review of 16 cases: Mast cell morphology determines clinical outcome
A. Pardanani, A. Tefferi, A. Al-Kali, M. Patnaik +10 more
2023American journal of hematology/oncology7 citations Open access
Semantic Scholar
A phase II study of combination daunorubicin, cytarabine (Ara‐c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression
A. Al-Kali, R. Tibes, P. Atherton, J. Palmer +7 more
2023American journal of hematology/oncology6 citations Open access
Semantic Scholar
Venetoclax in combination with fludarabine, cytarabine, granulocyte colony stimulating factor, and idarubicin (FLAG-Ida) in patients with acute leukemia of ambiguous lineage and acute lymphoblastic leukemia
Steven Tessier, Kristen B. McCullough, N. Gangat, K. Begna +7 more
2025Leukemia and Lymphoma5 citations
Semantic Scholar
Myeloid neoplasms with PHF6 mutations: context-dependent genomic and prognostic characterization in 176 informative cases
Saubia Fathima, Ali Alsugair, Rong He, A. Mangaonkar +6 more
2025Blood Cancer Journal5 citations Open access
Semantic Scholar
FLT3 inhibitors potentially improve response rates in acute myeloid leukemia harboring t(6;9)(DEK::NUP214): the Mayo Clinic experience
Clifford Csizmar, Antoine N. Saliba, P. Greipp, H. Alkhateeb +16 more
2024Haematologica5 citations Open access
Semantic Scholar
Black African-American patients with primary myelofibrosis: a comparative analysis of phenotype and survival
N. Gangat, A. Kuykendall, N. Al Ali, Swati Goel +12 more
2023Blood Advances5 citations Open access
Semantic Scholar
CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients
Saubia Fathima, L. Rokach, Nour Ghosoun, Mahsa RezaSoltani +26 more
2026Blood Cancer Journal4 citations Open access
Semantic Scholar
Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes
Clifford M. Csizmar, Anuya Natu, M. Gurney, Saubia Fathima +31 more
2025Leukemia4 citations
Semantic Scholar
The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia
Y. Alvarado-Valero, Rachel J. Cook, S. Dinner, M. Keng +10 more
2025Blood neoplasia4 citations Open access
Semantic Scholar
Prognostic impact of SF3B1 mutation and multilineage dysplasia in myelodysplastic syndromes with ring sideroblasts: a Mayo Clinic study of 170 informative cases
F. Farrukh, Maymona G. Abdelmagid, Abhishek Mangaonkar, Mrinal S. Patnaik +14 more
2024Haematologica4 citations Open access
Semantic Scholar
Comparison of World Health Organization and International Consensus Classification Guidelines for Myeloid Neoplasms Harboring TP53-Mutations Using an Independent International Cohort
M. Shah, M. Kutyna, S. Shah, E. Tran +27 more
2023Blood4 citations
Semantic Scholar
Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival
Maymona G. Abdelmagid, A. Al-Kali, K. Begna, W. Hogan +14 more
2023Haematologica4 citations Open access
Semantic Scholar
Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases
A. Tefferi, Maymona G. Abdelmagid, A. Al-Kali, M. Patnaik +7 more
2023American journal of hematology/oncology4 citations
Semantic Scholar
Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents
Saubia Fathima, Margaret Mei-Kay Wong, Jesus D. Gonzalez-Lugo, Susan M Geyer +45 more
2026American journal of hematology/oncology3 citations Open access
Semantic Scholar
Predictors of response to pacritinib therapy and survival among 60 Mayo Clinic patients with myelofibrosis treated outside of clinical trials
Maymona G. Abdelmagid, Jeanne M. Palmer, A. Al-Kali, M. Hefazi +6 more
2025Haematologica3 citations Open access
Semantic Scholar
Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant
A. Tefferi, A. Pardanani, K. Begna, A. Al-Kali +5 more
2024Blood Cancer Journal3 citations Open access
Semantic Scholar
DIPSS-R: A revised age-agnostic clinical risk model for chronic phase primary myelofibrosis
A. Tefferi, A. Vannucchi, Yassin Bashir, Ahmed A. Abdelrheem +14 more
2025Blood2 citations
Semantic Scholar
Evidence-Based Risk Stratification of TP53-Mutated Myeloid Neoplasms
M. Shah, Kevin Hung, A. Baranwal, Z. Price +30 more
2024Blood2 citations
Semantic Scholar
Optimal frontline therapy of chronic myeloid leukemia today, and related musings
H. Kantarjian, K. Begna, E. Jabbour, S. Paul +2 more
2024American journal of hematology/oncology2 citations
Semantic Scholar
A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Y. Alvarado-Valero, R. Cook, S. Dinner, M. Keng +9 more
2024Blood2 citations
Semantic Scholar
Molecular and Cytokine Correlates of Anemia Response to Treatment with DISC-0974 (An Anti-Hemojuvelin Antibody) in Non-Transfusion-Dependent Patients with Myelofibrosis
A. Tefferi, C. Hutchens, Antoine N. Saliba, G. G. Loscocco +7 more
2024Blood2 citations
Semantic Scholar
Survival and Prognosis Among 301 Patients with Newly-Diagnosed Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy
Omer S Karrar, Moazah Iftikhar, Kristen B. McCullough, I. Johnson +21 more
2023Blood2 citations
Semantic Scholar
TP53 Variant Allele Frequency and Therapy-Related Setting Independently Predict Survival in Myelodysplastic Syndromes with Del(5q)
Farah Fleti, O. Chan, N. Al Ali, A. Al-Kali +17 more
2023Blood2 citations Open access
Semantic Scholar
Outcomes of hemophagocytic lymphohistiocytosis in acute myeloid leukemia: the 3-site Mayo Clinic experience
Jabra Zarka, Clifford M. Csizmar, Syeda Mina, Ashley Hickman +16 more
2026Blood neoplasia1 citations Open access
Semantic Scholar
Treatment-specific prognostic performance of ELN 2022, ELN 2024, and Beat AML 2024: a real-world AML validation study
Tariq Kewan, Oudai Alkabbani, H. Zureigat, Rong He +16 more
2026Blood neoplasia1 citations Open access
Semantic Scholar
Life‐Threatening Acute Tumor Lysis Syndrome With Multiorgan Failure Following First Cycle of Bendamustine–Rituximab in Chronic Lymphocytic Leukemia: A Case Report and Brief Review
Malegna Temesgen Garuma, K. Begna, Tesfaye Amare, M. Desta +2 more
2026Clinical Case Reports1 citations Open access
Semantic Scholar
TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast‐Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent
N. Gangat, Momna Warraich, Sudhesh Kumar, Mahnoor Fatima +16 more
2026American journal of hematology/oncology1 citations Open access
Semantic Scholar
Treatment Pattern and Outcome of Locally Advanced Rectal Cancer in Resource-Constrained Countries: Experience at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia
Elias Amare Hailu, E. Woldetsadik, B. Tadesse, A. Dibaba +5 more
2025JCO Global Oncology1 citations Open access
Semantic Scholar
Predictors of post-transplant survival in patients with newly diagnosed acute myeloid leukemia receiving frontline venetoclax and hypomethylating agents.
I. Johnson, Azeem Elbeih, Nour Ghosoun, Kristen B. McCullough +15 more
2025Journal of Clinical Oncology1 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

N. Gangat×38
Invite
N. Gangat — researcher profile on SciRah
A. Al-Kali×34
Invite
A. Al-Kali — researcher profile on SciRah
A. Tefferi×25
Invite
A. Tefferi — researcher profile on SciRah
A. Pardanani×23
Invite
A. Pardanani — researcher profile on SciRah

×22

Invite

M. Shah — researcher profile on SciRah

H. Alkhateeb×20

Invite

H. Alkhateeb — researcher profile on SciRah

Invite

M. Litzow — researcher profile on SciRah

A. Mangaonkar×19

Invite

A. Mangaonkar — researcher profile on SciRah

Antoine N. Saliba×17

Invite

Antoine N. Saliba — researcher profile on SciRah

Talha Badar×16

Invite

Talha Badar — researcher profile on SciRah

William J. Hogan×15

Invite

William J. Hogan — researcher profile on SciRah

Invite

M. Patnaik — researcher profile on SciRah